Is immunoprophylaxis with palivizumab justified for respiratory syncytial virus?

被引：1
|
作者：
Paul, Siba P. [1 ]
Ball, Georgina M. [2 ]
机构：
[1] Torbay Hosp, Dept Paediat, Torquay TQ2 7AA, England
[2] Peninsula Coll Med & Dent, Plymouth, Devon, England
来源：
BRITISH JOURNAL OF HOSPITAL MEDICINE | 2017年 / 78卷 / 08期
关键词：
D O I：
10.12968/hmed.2017.78.8.476
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：476 / 476
页数：1
相关论文
共 50 条
  • [1] Effectiveness of palivizumab immunoprophylaxis in infants with respiratory syncytial virus disease in Colombia
    Gabriel Pineros, Juan
    De la Hoz-Valle, Jose
    Galvis, Clara
    Celis, Astrid
    Ovalle, Oscar
    Cecilia Sandoval, Carmen
    Orrego, Jaime
    Vides, Saby
    Rojas, Iader
    Bustamante, Hernando
    Gallon, Carlos
    Alberto Mesa, Jaime
    [J]. JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2021, 15 (11): : 1708 - 1713
  • [2] Annual variation in respiratory syncytial virus season and decisions regarding immunoprophylaxis with palivizumab
    Meissner, HC
    Anderson, LJ
    Pickering, LK
    [J]. PEDIATRICS, 2004, 114 (04) : 1082 - 1084
  • [3] Respiratory syncytial virus: Early immunoprophylaxis in NICU preterm infants using palivizumab
    Bonaparte, J
    Wu, SY
    Pyati, S
    [J]. PEDIATRIC RESEARCH, 2003, 53 (04) : 311A - 311A
  • [4] Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar
    Abushahin, Ahmad
    Janahi, Ibrahim
    Tuffaha, Amjad
    [J]. INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2018, 11 : 41 - 46
  • [5] Outcomes of Respiratory Syncytial Virus Immunoprophylaxis in Infants Using an Abbreviated Dosing Regimen of Palivizumab
    Lavoie, Pascal M.
    Solimano, Alfonso
    Taylor, Richard
    Kwan, Eddie
    Claydon, Jennifer
    Turvey, Stuart E.
    Marr, Nico
    [J]. JAMA PEDIATRICS, 2016, 170 (02) : 174 - 176
  • [6] Immunoprophylaxis for respiratory syncytial virus
    Sánchez, PJ
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (05) : 473 - 478
  • [7] Immunoprophylaxis with palivizumab for prevention of Respiratory Syncytial Virus infection: Indications for use and preliminary data
    Vagnarelli, F
    Vancini, A
    Mariani, S
    Magnani, C
    Banchini, G
    [J]. PERINATOLOGY 2001, VOLS 1 AND 2, 2001, : 1001 - 1003
  • [8] Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion
    Meissner, HC
    Welliver, RC
    Chartrand, SA
    Law, BJ
    Weisman, LE
    Dorkin, HL
    Rodriguez, WJ
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1999, 18 (03) : 223 - 231
  • [9] Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation
    Wang, D.
    Cummins, C.
    Bayliss, S.
    Sandercock, J.
    Burls, A.
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2008, 12 (36) : 1 - +
  • [10] PALIVIZUMAB FOR RESPIRATORY SYNCYTIAL VIRUS DISEASE
    Carrera, G.
    D'alterio, R.
    Leone, G.
    Zambetti, C.
    [J]. MINERVA PEDIATRICA, 2013, 65 (05) : 505 - 512
12345